Across these diverse cohorts encompassing various cancer types and therapeutic strategies, PSMB9 expression was consistently upregulated in responders relative to non-responders, with collective elevation of its expression levels in treatment-responsive groups, thereby providing initial evidence for a potential association with treatment response (Figure 6C, Supplementary Table S3). This evidence concerns the gene PSMB9 and cancer.